Novel Competitive Inhibitor of NAD(P)H Oxidase Assembly Attenuates Vascular O2−and Systolic Blood Pressure in Mice
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
We previously reported enhanced expression of the p67phoxand gp91phoxcomponents of NAD(P)H oxidase in angiotensin (Ang) II–induced hypertension, suggesting de novo assembly in response to Ang II. To examine the direct involvement of NAD(P)H oxidases in Ang II–induced O 2−production, we designed a chimeric peptide that inhibits p47phoxassociation with gp91phoxin NAD(P)H oxidase (gp91ds-tat). This was achieved by linking a 9-amino acid peptide (aa) derived from HIV-coat protein (tat) to a 9-aa sequence of gp91phox(known to interact with p47phox). As a control, we constructed a chimera containing tat and a scrambled gp91 sequence (scramb-tat). We found that gp91ds-tat decreased O 2−levels in aortic rings treated with Ang II (10 pmol/L) but had no effect on either the O 2−-generating enzyme xanthine oxidase or potassium superoxide–generated O 2−. We infused vehicle, Ang II (0.75 mg · kg−1· d−1), Ang II+gp91ds-tat(10 mg · kg−1· d−1), or Ang II+scramb-tat intraperitoneally in C57Bl/6 mice and measured systolic blood pressure (SBP) on days 0, 3, 5, and 7 of infusion. SBP increased by day 3 in mice given Ang II and Ang II+scramb-tat but was significantly lower with Ang II+gp91-tat. On day 7, SBP was still significantly inhibited in mice given Ang II+gp91ds-tat, whereas Ang II–induced O 2−production was inhibited throughout the aorta as detected by dihydroethidium staining, consistent with the ability of this inhibitor to block the various vascular NAD(P)H oxidase isoforms. These data support the hypothesis that inhibition of the interaction of p47phoxand gp91phox(or its homologues) can block O 2−production and attenuate blood pressure elevation in mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NAD(P)H Oxidase: Role in Cardiovascular Biology and Disease
Griendling, K. K., Sorescu, D., & Ushio-Fukai, M. (2000) · Circulation Research · doi:10.1161/01.res.86.5.494 · Cited by 2,886
Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells.
Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D., & Alexander, R. W. (1994) · Circulation Research · doi:10.1161/01.res.74.6.1141 · Cited by 2,735
Rajagopalan, S., Kurz, S., Münzel, T., Tarpey, M., Freeman, B. A., Griendling, K. K., & Harrison, D. G. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118623 · Cited by 2,449
Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor
Gryglewski, R. J., Palmer, R. M. J., & Moncada, S. (1986) · Nature · doi:10.1038/320454a0 · Cited by 2,400
Cell transformation by the superoxide-generating oxidase Mox1
Suh, Y.-A., Arnold, R. S., Lassegue, B., Shi, J., Xu, X., Sorescu, D., Chung, A. B., Griendling, K. K., & Lambeth, J. D. (1999) · Nature · doi:10.1038/43459 · Cited by 1,480
Tat-mediated delivery of heterologous proteins into cells.
Fawell, S., Seery, J., Daikh, Y., Moore, C., Chen, L. L., Pepinsky, B., & Barsoum, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.2.664 · Cited by 1,225
Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor
Rubanyi, G. M., & Vanhoutte, P. M. (1986) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1986.250.5.h822 · Cited by 1,188
Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases
Kim, S., & Iwao, H. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01434-0 · Cited by 983
Identification of Renox, an NAD(P)H oxidase in kidney
Geiszt, M., Kopp, J. B., Várnai, P., & Leto, T. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130135897 · Cited by 842
Lassègue, B., Sorescu, D., Szöcs, K., Yin, Q., Akers, M., Zhang, Y., Grant, S. L., Lambeth, J. D., & Griendling, K. K. (2001) · Circulation Research · doi:10.1161/hh0901.090299 · Cited by 839
Cited by
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
Bedard, K., & Krause, K.-H. (2007) · Physiological Reviews · doi:10.1152/physrev.00044.2005 · Cited by 6,989
Oxidative Stress and Vascular Disease
Madamanchi, N. R., Vendrov, A., & Runge, M. S. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000150649.39934.13 · Cited by 1,618
Ying, W. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1672 · Cited by 1,494
Reperfusion injury and reactive oxygen species: The evolution of a concept
Granger, D. N., & Kvietys, P. R. (2015) · Redox Biology · doi:10.1016/j.redox.2015.08.020 · Cited by 1,484
Inflammatory cytokines in vascular dysfunction and vascular disease
Sprague, A. H., & Khalil, R. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.029 · Cited by 1,352
Cysteine-Mediated Redox Signaling: Chemistry, Biology, and Tools for Discovery
Paulsen, C. E., & Carroll, K. S. (2013) · Chemical Reviews · doi:10.1021/cr300163e · Cited by 1,278
Vascular NAD(P)H oxidases: specific features, expression, and regulation
Lassègue, B., & Clempus, R. E. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00758.2002 · Cited by 1,032
NADPH oxidases: An overview from structure to innate immunity-associated pathologies
Panday, A., Sahoo, M. K., Osorio, D., & Batra, S. (2015) · Cellular & Molecular Immunology · doi:10.1038/cmi.2014.89 · Cited by 944
Oxidative Stress and Cardiovascular Injury: Part I: Basic Mechanisms and In Vivo Monitoring of ROS
Griendling, K. K., & FitzGerald, G. A. (2003) · Circulation · doi:10.1161/01.cir.0000093660.86242.bb · Cited by 941
Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets
Drummond, G. R., Selemidis, S., Griendling, K. K., & Sobey, C. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3403 · Cited by 899
Cross talk between mitochondria and NADPH oxidases
Dikalov, S. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.06.033 · Cited by 783
Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology
Li, J.-M., & Shah, A. M. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00124.2004 · Cited by 773
“Studies in hypertensive models associated with activation of the renin-angiotensin system have convincingly shown that increased NADPH oxidase activity (at least in part due to increased subunit expression) contributes both to endothelial dysfunction and elevation of blood pressure per se (21, 50, 85, 90, 100, 132).”
BackgroundBiochemistry, Physiology, and Pathophysiology of NADPH Oxidases in the Cardiovascular System
Lassègue, B., San Martín, A., & Griendling, K. K. (2012) · Circulation Research · doi:10.1161/circresaha.111.243972 · Cited by 767
NADPH Oxidases, Reactive Oxygen Species, and Hypertension
Paravicini, T. M., & Touyz, R. M. (2008) · Diabetes Care · doi:10.2337/dc08-s247 · Cited by 724
Oxidative Stress and Cardiovascular Injury: Part II: Animal and Human Studies
Griendling, K. K., & FitzGerald, G. A. (2003) · Circulation · doi:10.1161/01.cir.0000093661.90582.c4 · Cited by 721
The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases
Cai, H., Griendling, K. K., & Harrison, D. G. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00233-5 · Cited by 687
Nox family NADPH oxidases: Molecular mechanisms of activation
Brandes, R. P., Weissmann, N., & Schröder, K. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.07.046 · Cited by 673
NADPH Oxidases in Cardiovascular Health and Disease
Cave, A. C., Brewer, A. C., Narayanapanicker, A., Ray, R., Grieve, D. J., Walker, S., & Shah, A. M. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.691 · Cited by 630
“In short-term Ang II-induced hypertension in mice, the infusion of a peptide inhibitor of NADPH oxidase attenuated the rise in blood pressure (286).”
BackgroundNox4 Is a Protective Reactive Oxygen Species Generating Vascular NADPH Oxidase
Schröder, K., Zhang, M., Benkhoff, S., Mieth, A., Pliquett, R., Kosowski, J., Kruse, C., Luedike, P., Michaelis, U. R., Weissmann, N., et al. (2012) · Circulation Research · doi:10.1161/circresaha.112.267054 · Cited by 622
DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88
Tarallo, V., Hirano, Y., Gelfand, B. D., Dridi, S., Kerur, N., Kim, Y., Cho, W. G., Kaneko, H., Fowler, B. J., Bogdanovich, S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.036 · Cited by 592
Touyz, R. M., Chen, X., Tabet, F., Yao, G., He, G., Quinn, M. T., Pagano, P. J., & Schiffrin, E. L. (2002) · Circulation Research · doi:10.1161/01.res.0000020404.01971.2f · Cited by 590
Self-citationRedox signaling in hypertension
PARAVICINI, T., & TOUYZ, R. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.05.001 · Cited by 577
Role of p47 phox in Vascular Oxidative Stress and Hypertension Caused by Angiotensin II
Landmesser, U., Cai, H., Dikalov, S., McCann, L., Hwang, J., Jo, H., Holland, S. M., & Harrison, D. G. (2002) · Hypertension · doi:10.1161/01.hyp.0000032100.23772.98 · Cited by 577
X-ROS Signaling: Rapid Mechano-Chemo Transduction in Heart
Prosser, B. L., Ward, C. W., & Lederer, W. J. (2011) · Science · doi:10.1126/science.1202768 · Cited by 564
Aging-Induced Phenotypic Changes and Oxidative Stress Impair Coronary Arteriolar Function
Csiszar, A., Ungvari, Z., Edwards, J. G., Kaminski, P., Wolin, M. S., Koller, A., & Kaley, G. (2002) · Circulation Research · doi:10.1161/01.res.0000020401.61826.ea · Cited by 563
The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease
Shirai, T., Nazarewicz, R. R., Wallis, B. B., Yanes, R. E., Watanabe, R., Hilhorst, M., Tian, L., Harrison, D. G., Giacomini, J. C., Assimes, T. L., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20150900 · Cited by 543
Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation
Tejero, J., Shiva, S., & Gladwin, M. T. (2019) · Physiological Reviews · doi:10.1152/physrev.00036.2017 · Cited by 541
NADPH oxidases and oxidase crosstalk in cardiovascular diseases: novel therapeutic targets
Zhang, Y., Murugesan, P., Huang, K., & Cai, H. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0260-8 · Cited by 534
Zielonka, J., & Kalyanaraman, B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.01.028 · Cited by 531
Regulation of NADPH Oxidases: The Role of Rac Proteins
Hordijk, P. L. (2006) · Circulation Research · doi:10.1161/01.res.0000204727.46710.5e · Cited by 525
Evolution of nadph oxidase inhibitors: Selectivity and mechanisms for target engagement
Altenhöfer, S., Radermacher, K. A., Kleikers, P. W. M., Wingler, K., & Schmidt, H. H. H. W. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5814 · Cited by 521
Wenzel, P., Knorr, M., Kossmann, S., Stratmann, J., Hausding, M., Schuhmacher, S., Karbach, S. H., Schwenk, M., Yogev, N., Schulz, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.034470 · Cited by 504
The NADPH oxidase of professional phagocytes—prototype of the NOX electron transport chain systems
Cross, A. R., & Segal, A. W. (2004) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2004.03.008 · Cited by 489
Quinn, M. T., & Gauss, K. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0404216 · Cited by 480
Self-citationReactive oxygen species and vascular biology: implications in human hypertension
Touyz, R. M., & Briones, A. M. (2011) · Hypertension Research · doi:10.1038/hr.2010.201 · Cited by 470
Delivery of bioactive molecules into the cell: the Trojan horse approach
Dietz, G. P. H., & Bähr, M. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.03.005 · Cited by 469
Gill, P. S., & Wilcox, C. S. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.1597 · Cited by 457
NADPH Oxidases in Vascular Pathology
Konior, A., Schramm, A., Czesnikiewicz-Guzik, M., & Guzik, T. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5607 · Cited by 452
Mechanisms of Disease: oxidative stress and inflammation in the pathogenesis of hypertension
Vaziri, N. D., & Rodríguez-Iturbe, B. (2006) · Nature Clinical Practice Nephrology · doi:10.1038/ncpneph0283 · Cited by 442
Dikalova, A., Clempus, R., Lassègue, B., Cheng, G., McCoy, J., Dikalov, S., Martin, A. S., Lyle, A., Weber, D. S., Weiss, D., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.538934 · Cited by 438
NADPH oxidase in brain injury and neurodegenerative disorders
Ma, M. W., Wang, J., Zhang, Q., Wang, R., Dhandapani, K. M., Vadlamudi, R. K., & Brann, D. W. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0150-7 · Cited by 432
Münzel, T., Daiber, A., Ullrich, V., & Mülsch, A. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000168896.64927.bb · Cited by 410
Characterisation of cell‐penetrating peptide‐mediated peptide delivery
Jones, S. W., Christison, R., Bundell, K., Voyce, C. J., Brockbank, S. M. V., Newham, P., & Lindsay, M. A. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706279 · Cited by 385
Lin, V. S., Lippert, A. R., & Chang, C. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302193110 · Cited by 376
The Role of NADPH Oxidases and Oxidative Stress in Neurodegenerative Disorders
Tarafdar, A., & Pula, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123824 · Cited by 373
NADPH Oxidases of the Brain: Distribution, Regulation, and Function
Infanger, D. W., Sharma, R. V., & Davisson, R. L. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.1583 · Cited by 362
Microglial/Macrophage Polarization Dynamics following Traumatic Brain Injury
Kumar, A., Alvarez-Croda, D.-M., Stoica, B. A., Faden, A. I., & Loane, D. J. (2016) · Journal of Neurotrauma · doi:10.1089/neu.2015.4268 · Cited by 339
Park, L., Zhou, P., Pitstick, R., Capone, C., Anrather, J., Norris, E. H., Younkin, L., Younkin, S., Carlson, G., McEwen, B. S., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711568105 · Cited by 332
Cell Penetrating Peptides in Drug Delivery
Snyder, E. L., & Dowdy, S. F. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000019289.61978.f5 · Cited by 323
Münzel, T., Feil, R., Mülsch, A., Lohmann, S. M., Hofmann, F., & Walter, U. (2003) · Circulation · doi:10.1161/01.cir.0000094403.78467.c3 · Cited by 316
Endothelial NADPH oxidases: which NOX to target in vascular disease?
Drummond, G. R., & Sobey, C. G. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.06.012 · Cited by 315
Mechanism of Endothelial Cell NADPH Oxidase Activation by Angiotensin II
Li, J.-M., & Shah, A. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209793200 · Cited by 307
Ni, R., Cao, T., Xiong, S., Ma, J., Fan, G.-C., Lacefield, J. C., Lu, Y., Tissier, S. L., & Peng, T. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.11.013 · Cited by 288
De Logu, F., Nassini, R., Materazzi, S., Carvalho Gonçalves, M., Nosi, D., Rossi Degl’Innocenti, D., Marone, I. M., Ferreira, J., Li Puma, S., Benemei, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01739-2 · Cited by 283
Shelat, P. B., Chalimoniuk, M., Wang, J., Strosznajder, J. B., Lee, J. C., Sun, A. Y., Simonyi, A., & Sun, G. Y. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05347.x · Cited by 283
Sakellariou, G. K., Vasilaki, A., Palomero, J., Kayani, A., Zibrik, L., McArdle, A., & Jackson, M. J. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4623 · Cited by 276
“Scrambled-tat-pretreated fibers also showed a decrease in fluorescence following contractions, but some previous studies have also observed this (57).”
Nox2-Derived Reactive Oxygen Species Mediate Neurovascular Dysregulation in the Aging Mouse Brain
Park, L., Anrather, J., Girouard, H., Zhou, P., & Iadecola, C. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600491 · Cited by 275
“In these experiments, we used the NADPH oxidase peptide inhibitor gp91ds-tat (Kazama et al, 2004; Park et al, 2005; Rey et al, 2001) to establish whether the age-related alterations in neurovascular function are mediated by NADPH oxidase.”
MethodMontezano, A. C., & Touyz, R. M. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5302 · Cited by 270
NADPH oxidases in cardiovascular disease
Brandes, R. P., Weissmann, N., & Schröder, K. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.04.030 · Cited by 266
NAD(P)H oxidase–dependent platelet superoxide anion release increases platelet recruitment
Krötz, F., Sohn, H. Y., Gloe, T., Zahler, S., Riexinger, T., Schiele, T. M., Becker, B. F., Theisen, K., Klauss, V., & Pohl, U. (2002) · Blood · doi:10.1182/blood.v100.3.917 · Cited by 262
TENFREYHAUS, H., HUNTGEBURTH, M., WINGLER, K., SCHNITKER, J., BAUMER, A., VANTLER, M., BEKHITE, M., WARTENBERG, M., SAUER, H., & ROSENKRANZ, S. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.01.022 · Cited by 259
“Peptidic inhibitors like gp91ds-tat are useful in experimental procedures [19,30], but cannot be administered orally.”
BackgroundMicrotubules Underlie Dysfunction in Duchenne Muscular Dystrophy
Khairallah, R. J., Shi, G., Sbrana, F., Prosser, B. L., Borroto, C., Mazaitis, M. J., Hoffman, E. P., Mahurkar, A., Sachs, F., Sun, Y., et al. (2012) · Science Signaling · doi:10.1126/scisignal.2002829 · Cited by 259
gp91phox-Containing NADPH Oxidase Mediates Endothelial Dysfunction in Renovascular Hypertension
Jung, O., Schreiber, J. G., Geiger, H., Pedrazzini, T., Busse, R., & Brandes, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000124223.00113.a4 · Cited by 255
Angiotensin II Impairs Neurovascular Coupling in Neocortex Through NADPH Oxidase–Derived Radicals
Kazama, K., Anrather, J., Zhou, P., Girouard, H., Frys, K., Milner, T. A., & Iadecola, C. (2004) · Circulation Research · doi:10.1161/01.res.0000148637.85595.c5 · Cited by 253
Park, L., Anrather, J., Zhou, P., Frys, K., Pitstick, R., Younkin, S., Carlson, G. A., & Iadecola, C. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5207-04.2005 · Cited by 244
Comparative pharmacology of chemically distinct nadph oxidase inhibitors
Wind, S., Beuerlein, K., Eucker, T., Müller, H., Scheurer, P., Armitage, M., Ho, H., Schmidt, H., & Wingler, K. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00920.x · Cited by 241
“, 2001), which interferes with cytosolic subunit translocation and activation of NOX2, inhibits angiotensin II-induced aortic superoxide production and hypertension in vivo (Rey et al., 2001).”
BackgroundZhang, J., Malik, A., Choi, H. B., Ko, R. W. Y., Dissing-Olesen, L., & MacVicar, B. A. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.043 · Cited by 234
Jung, O., Marklund, S. L., Geiger, H., Pedrazzini, T., Busse, R., & Brandes, R. P. (2003) · Circulation Research · doi:10.1161/01.res.0000092140.81594.a8 · Cited by 223
Kumar, A., Barrett, J. P., Alvarez-Croda, D.-M., Stoica, B. A., Faden, A. I., & Loane, D. J. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.07.158 · Cited by 213
Nox enzymes as novel targets for drug development
Lambeth, J. D., Krause, K.-H., & Clark, R. A. (2008) · Seminars in Immunopathology · doi:10.1007/s00281-008-0123-6 · Cited by 212
Zhang, Q.-G., Laird, M. D., Han, D., Nguyen, K., Scott, E., Dong, Y., Dhandapani, K. M., & Brann, D. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034504 · Cited by 211
Classical Inhibitors of NOX NAD(P)H Oxidases Are Not Specific
Aldieri, E., Riganti, C., Polimeni, M., Gazzano, E., Lussiana, C., Campia, I., & Ghigo, D. (2008) · Current Drug Metabolism · doi:10.2174/138920008786049285 · Cited by 201
Wei, Y., Sowers, J. R., Clark, S. E., Li, W., Ferrario, C. M., & Stump, C. S. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00456.2007 · Cited by 197
“The peptide interferes with the binding of the cytosolic subunit p47 with the membrane subunit gp91 (Nox2) and inhibits NADPH oxidase activation (18, 32).”
BackgroundReactive oxygen species in the neuropathogenesis of hypertension
Peterson, J. R., Sharma, R. V., & Davisson, R. L. (2006) · Current Hypertension Reports · doi:10.1007/s11906-006-0056-1 · Cited by 139
Capone, C., Faraco, G., Park, L., Cao, X., Davisson, R. L., & Iadecola, C. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00679.2010 · Cited by 136
Nox2 B-loop peptide, Nox2ds, specifically inhibits the NADPH oxidase Nox2
Csányi, G., Cifuentes-Pagano, E., Al Ghouleh, I., Ranayhossaini, D. J., Egaña, L., Lopes, L. R., Jackson, H. M., Kelley, E. E., & Pagano, P. J. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.04.025 · Cited by 131
“Because these studies were carried out in cell-free systems, it is important to note that the peptides used in this study did not require a chimeric design containing the tat peptide for cell permeation [12,27].”
InfluentialSelf-citationSenescence-Induced Oxidative Stress Causes Endothelial Dysfunction
Bhayadia, R., Schmidt, B. M. W., Melk, A., & Hömme, M. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glv008 · Cited by 126
Nox1, 2, 4, 5: Counting out oxidative stress
Wingler, K., Hermans, J., Schiffers, P., Moens, A., Paul, M., & Schmidt, H. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01249.x · Cited by 113
“A more reliable tool to inhibit NADPH oxidases are cellpermeable peptide-based inhibitors such as gp91ds-tat (Rey et al., 2001), whereas another peptide inhibitor, the naturally occurring peptide PR-39 (Gudmundsson et al.”
InfluentialTo, E. E., Erlich, J. R., Liong, F., Luong, R., Liong, S., Esaq, F., Oseghale, O., Anthony, D., McQualter, J., Bozinovski, S., et al. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7727 · Cited by 88
The Quest for Selective Nox Inhibitors and Therapeutics: Challenges, Triumphs and Pitfalls
Cifuentes-Pagano, E., Meijles, D. N., & Pagano, P. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5620 · Cited by 84
Self-citationBoslett, J., Hemann, C., Christofi, F. L., & Zweier, J. L. (2018) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00139.2017 · Cited by 65
“Interestingly, pretreatment with the specific NADPH oxidase inhibiting TAT-peptide gp91ds-TAT (20 M) that has been shown to fully inhibit activity (15, 38) had no significant effect on the magnitude of superoxide generation in rat aortic ECs undergoing H/R.”
BackgroundMethodRole of NOX2 in the regulation of afferent arteriole responsiveness
Carlström, M., Lai, E. Y., Ma, Z., Patzak, A., Brown, R. D., & Persson, A. E. G. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90718.2008 · Cited by 65
Roos, C. M., Hagler, M., Zhang, B., Oehler, E. A., Arghami, A., & Miller, J. D. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00735.2012 · Cited by 54
Csányi, G., & Pagano, P. J. (2013) · International Journal of Hypertension · doi:10.1155/2013/842827 · Cited by 20
Self-citation
Metadata
- Authors
- Rey, F. E., Cifuentes, M. E., Kiarash, A., Quinn, M. T., & Pagano, P. J.
- Venue
- Circulation Research
- Published
- 2001-08-31
- Volume
- 89
- Issue
- 5
- Pages
- 408-414
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2107509703
- Cited by
- 605
- References
- 48
- FWCI
- 11.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.